by Okapit | Nov 11, 2026 | Latest news, News
Helsinki, Finland, 10.11.2026 Rokote Laboratories Finland Oy and GlobeVAC Oy have entered into a strategic collaboration to evaluate the application of GlobeVAC’s stabilization technology to the FINVAC intranasal vaccine platform. The objective of the...
by Okapit | Dec 18, 2025 | Latest news, News
Rokote Laboratories Finland Oy is proud to announce that we have received Clinical Trial Authorization (CTA) for our second Phase I clinical trial of the intranasal COVID-19 vaccine. The upcoming study, titled:”A Phase 1a, single-blind, randomized comparative...
by Okapit | Nov 26, 2025 | Latest news, News
We are pleased to announce the appointment of Terhi Reunama as our new Head of Clinical Trial Operations. Terhi brings nearly 30 years of clinical research experience from both the pharmaceutical industry and CRO organizations. A registered nurse with a Bachelor of...
by Okapit | Jul 18, 2024 | News
The development of the nasal COVID-19 vaccine by the Finnish vaccine development company Rokote Laboratories Finland Oy has successfully progressed to the stage where the company has submitted an application for its first clinical trial. Rokote Laboratories Finland Oy...
by Okapit | Dec 9, 2023 | News
Finnish vaccine development company Rokote Laboratories Finland Oy is pleased to announce the appointment of its Research and Development Director, Erkko Ylösmäki, as the new CEO, effective January 1, 2024. The company plans to initiate clinical trials for its vaccine...
by Okapit | Oct 27, 2023 | News
The European Society of Gene and Cell Therapy (ESGCT) board honors Professor Seppo Ylä-Herttuala for his exceptional career achievements and has selected him as the winner of the 2023 ESGCT Outstanding Achievement Award. The award is the most prestigious award...
